Clinical Trial

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-06-30 -> 2028-06-30 2026-08-04
Trial Details
NCT Number NCT07680582
Lead Sponsor Ruijin Hospital
Collaborators: Abogen Life Sciences (Shanghai) Co., Ltd., Suzhou Abogen Biosciences Co., Ltd.
Conditions Solid Tumor
Enrollment 60 participants
Start Date 2026-06-09
Primary Completion 2028-06-30 (estimated)
Study Completion 2031-02-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-03